VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 possesses anti-inflammatory properties and effectively reduced the symptoms of arthritis in experimental models. These results were presented today at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, by Niva Yacov, M.Sc., project manager at VBL.
“We are pleased to have the opportunity to present these data to the rheumatology community, who are well aware of the devastating nature of rheumatoid arthritis”
VB-201 is the first in a new class of drugs and the lead candidate of several proprietary phospholipid analogs from VBL's proprietary Lecinoxoid family that were designed to be orally available, anti-inflammatory medicines. Oxidized phospholipids are abundantly generated in sites of inflammation, but unlike native oxidized phospholipids, which induce inflammation in rheumatoid arthritis and other chronic inflammatory diseases, Lecinoxoids exhibit anti-inflammatory properties.
"We are pleased to have the opportunity to present these data to the rheumatology community, who are well aware of the devastating nature of rheumatoid arthritis," said Professor Dror Harats, M.D., chief executive officer of VBL. "Today's results are an important part of the VB-201 story and were instrumental in the decision to move forward with our phase 2 clinical trial in patients with psoriasis, which we look forward to sharing."